Research use only. Hexarelin is an unapproved research compound, and we found no approved human indication for it. This content is for educational purposes and does not constitute medical advice. Consult a licensed healthcare provider before use.

What the human studies used

Hexarelin is a synthetic hexapeptide, His-D-2-methylTrp-Ala-Trp-D-Phe-Lys-NH2, and the 1997 comparison with GHRP-2 describes it as a super-analog of GHRP-6. There is no label and no dose-finding programme for it. What exists is a set of small physiology studies from the 1990s, and every figure below comes from them.

StudySubjectsDose and routeResult reported
Ghigo 199412 healthy young volunteers, single doses1 and 2 mcg/kg IV; 1.5 and 3 mcg/kg SCGH response (AUC, mcg/min/L): IV 3,175 and 4,422; SC 3,180 and 4,459. GHRH at 1 mcg/kg gave 1,544
Ghigo 1994 (same study)Same20 mcg/kg intranasal; 20 and 40 mg oralGH response 2,642 intranasal; 2,278 and 4,079 oral. Bioavailability 77.0% SC, 4.8% intranasal, 0.3% oral
Ghigo 1996Seven older adults, then seven older women1.25 mg intranasal three times daily for 8 days; 20 mg oral three times daily for 15 daysGH response maintained after treatment; no change in prolactin or cortisol; no side effects reported
Rahim 1998Healthy adults, 16 weeks1.5 mcg/kg SC twice dailyGH response fell over time (next table); IGF-I, body fat, lean mass and bone density unchanged at 16 weeks

Two things stand out. The growth hormone response rose with dose over 1 to 3 mcg/kg, so the claim that the receptor saturates near 100 mcg is not supported by the human data we found. And subcutaneous delivery had 77 percent of the bioavailability of intravenous, while oral delivery had 0.3 percent, which is why the oral studies needed milligram doses. Ghigo's 2 mcg/kg intravenous dose was reproducible on repeat testing (AUC 4,016 and 3,959).

How fast the response fades

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

In the 16-week study, healthy adults injected 1.5 mcg/kg subcutaneously twice daily, and the researchers tested the growth hormone response to a single dose at intervals.

Week0141620 (4 weeks after stopping)
GH response to a test dose (AUC, mcg/L per hour)19.113.112.310.519.4

The decline was already significant at week 4 and week 16, and it reversed after a four-week break, so the authors called it a partial and reversible attenuation. IGF-I and IGF binding protein-3 did not change significantly, and body fat, lean mass and bone mineral density were unchanged at 16 weeks. A study of two intravenous boluses found a smaller second response at a 120 minute interval, and a 1995 study found repeated hexarelin reduced the response by less than repeated GHRH did. By contrast, the intermittent 8-day and 15-day regimens in older adults kept the response. For how the same problem is handled with other secretagogues, see the ipamorelin guide, MK-677 and sermorelin; for a GHRH partner, see CJC-1295 dosage. The same 1996 study found hexarelin and GHRH together released more GH than the sum of either alone, a synergy that was lost on repeat dosing.

Cortisol and prolactin

Hexarelin is not specific for growth hormone. In a 1997 study of six young adults, 1 and 2 mcg/kg intravenous hexarelin and GHRP-2 raised prolactin, ACTH and cortisol, and the authors compared the ACTH and cortisol effect with that of CRH. Chronic dosing looked different. After 16 weeks of 1.5 mcg/kg twice daily, the cortisol area under the curve fell from 1,506 to 1,222 nmol/L per hour, returned toward baseline four weeks after stopping, and prolactin was unchanged. Urinary free cortisol did not change, so the authors judged the shift unlikely to be clinically significant. The studies we reviewed did not test repeated doses above 3 mcg/kg, so claims that 200 mcg or more is worse are not supported here.

CD36 and the cardiac research

Hexarelin also binds CD36, a scavenger receptor, which is why it has a cardiac literature that other secretagogues lack. The table separates animal and cell work from the small human studies. All the human cardiac studies are single intravenous doses, none measured outcomes such as events, and the animal result is a rise in coronary perfusion pressure, which the authors linked to vasospasm risk in atherosclerosis.

StudyModelWhat was doneFinding
Bodart 2002Rat and mouse hearts (animal)Hexarelin on perfused hearts; CD36 knockout miceCoronary perfusion pressure rose with dose; the effect was absent without CD36
Avallone 2006Macrophages (cell culture)Hexarelin on cultured macrophagesRaised cholesterol transporter expression and cholesterol efflux via a CD36 and PPAR-gamma pathway
Broglio 200224 men with coronary artery disease, under anaesthesia2 mcg/kg IV onceHigher ejection fraction, cardiac index and output for up to 90 minutes; GHRH and GH did not do this
Imazio 200213 patients with cardiomyopathy, compared with 7 healthy and 7 GH-deficient peopleIV hexarelin onceEjection fraction rose in ischemic cardiomyopathy, not in dilated cardiomyopathy

Syringe units for 2 mg and 5 mg vials

Calculate your draw for hexarelin

Enter the vial strength, the bacteriostatic water you added and your dose, and get the exact mark on the syringe. Free, no signup, and the result comes with a link you can share or save.

Open the hexarelin calculator peptulator.com, the Bureau's independent tool

On a U-100 insulin syringe, units equal dose in mg divided by concentration in mg/mL, times 100. The 100 mcg and 200 mcg columns are arithmetic for the nearest round numbers to the 1.5 and 3 mcg/kg subcutaneous doses in a 70 kg adult (105 and 210 mcg), and are not recommendations.

VialWater addedConcentration (mg/mL)mcg per unitUnits for 100 mcgUnits for 200 mcg
2 mg1 mL220510
2 mg2 mL1101020
2 mg3 mL0.676.671530
5 mg1 mL55024
5 mg2 mL2.52548
5 mg3 mL1.6716.67612

Use the reconstitution calculator for other vial sizes, and see how to reconstitute peptides and the peptide storage guide for handling.

Disclosure: affiliate links below may earn the Bureau a commission at no cost to you.

What these cost at Amino Club

List prices on 2026-09-08, before any code; Amino Club is the vendor Bureau readers order from most. Partner code 100 at checkout takes 20% off there, and keeps the order counted for the Bureau. Research use only.

Ipamorelin 10mg · $49.99 CJC-1295 / Ipamorelin (no DAC) 10mg · $59.99

Safety and what is not known

The 1996 study in older adults reported no side effects, and the other abstracts we read do not describe adverse events in detail. All of them were short, small and run in healthy volunteers or patients under monitoring. No long-term safety data exist, and the broader class issues are covered in peptide side effects. For a GHRH analogue against a ghrelin mimetic, see sermorelin vs GHRP-6. The muscle growth peptides page places hexarelin among the other secretagogues, and the stack builder is the place to compare combinations.

Frequently Asked Questions

What dose of hexarelin was used in human studies?

Single-dose studies in healthy volunteers used 1 and 2 mcg/kg intravenously and 1.5 and 3 mcg/kg subcutaneously, and the growth hormone response rose with dose across those ranges. The 16-week study used 1.5 mcg/kg subcutaneously twice daily. Those are trial doses in a research setting, not recommendations.

Does hexarelin stop working?

Partly, and reversibly. In a 16-week study with 1.5 mcg/kg subcutaneously twice daily, the growth hormone response fell from 19.1 to 10.5 mcg/L per hour and was back to 19.4 four weeks after the last dose. Two shorter studies in older adults using intermittent dosing for 8 and 15 days found no loss of response.

Does hexarelin raise cortisol and prolactin?

After a single intravenous dose, yes: a 1997 comparison found hexarelin raised prolactin, ACTH and cortisol in a similar way to GHRP-2. After 16 weeks of twice-daily dosing, the cortisol response to a dose was lower than at baseline and the prolactin response was unchanged.

How many units is 100 mcg of hexarelin on an insulin syringe?

It depends on the vial and water. A 2 mg vial with 2 mL of water is 1 mg/mL, so 100 mcg is 0.1 mL, or 10 units on a U-100 syringe. A 5 mg vial with 2 mL is 2.5 mg/mL, so the same 100 mcg is 4 units.

Is hexarelin the same as GHRP-6?

No. Hexarelin is a six amino acid analogue of GHRP-6 with a methyl group on the second tryptophan, and a 1997 study describes it and GHRP-2 as super-analogs of GHRP-6. Both act on the same receptor family. Our GHRP-6 guide covers the parent compound.

Sources

  1. Ghigo et al, growth hormone-releasing activity of hexarelin after intravenous, subcutaneous, intranasal and oral administration in man, J Clin Endocrinol Metab, 1994
  2. Ghigo et al, short-term administration of intranasal or oral hexarelin does not desensitize the growth hormone responsiveness in human aging, Eur J Endocrinol, 1996
  3. Rahim et al, growth hormone status during long-term hexarelin therapy, J Clin Endocrinol Metab, 1998
  4. Rahim et al, the effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin, Clin Endocrinol, 1999
  5. Massoud et al, the effect of repeated administration of hexarelin and growth hormone releasing hormone on growth hormone responsivity, Clin Endocrinol, 1996
  6. Sartorio et al, GH responsiveness to repeated GHRH or hexarelin administration in normal adults, J Endocrinol Invest, 1995
  7. Arvat et al, effects of GHRP-2 and hexarelin on GH, prolactin, ACTH and cortisol levels in man, Peptides, 1997
  8. Bodart et al, CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart, Circ Res, 2002
  9. Broglio et al, effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease, Eur J Pharmacol, 2002
  10. Imazio et al, GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction, Eur J Heart Fail, 2002
  11. Avallone et al, a growth hormone-releasing peptide that binds CD36 and the ghrelin receptor upregulates sterol transporters in macrophages, Mol Endocrinol, 2006